Table 1.
Baseline characteristics of subjects according to CC and AC genotyping of ABCG2 SNP
| CC genotype (n=46) | AC genotype (n=10) | P-value | |
|---|---|---|---|
|
| |||
| Age, years (mean ± SD) | 63±11 | 52±18.7 | 0.01b |
| Females, n (%) | 32 (69.6) | 7 (70.0) | 0.98 |
| Hypertension treatment, n (%) | 15 (32.6) | 1 (10.0) | 0.15 |
| BMI (kg/m3) | 27.4±0.62 | 25.7±1.4 | 0.27 |
| MTX dose (mg/week) | 14.5±0.56 | 14±1.2 | 0.72 |
| aMTXPGs (nmol/L packed RBCs) | 116.3±7 | 144.3±15.3 | 0.10 |
| CRP (mg/L) | 7±1.4 | 3.9±3.2 | 0.40 |
| DAS28 score | 2.8±1.1 | 2.6±0.2 | 0.55 |
| Stanford HAQ score | 0.69±0.08 | 0.89±0.18 | 0.33 |
| Clinical peripheral SBP (mmHg) | 127.2±1.5 | 117±3.5 | 0.01b |
| Clinical peripheral DBP (mmHg) | 74.1±1.1 | 69±2.5 | 0.07b |
| Clinical central SBP (mmHg) | 117.9±1.4 | 107±3.2 | 0.003c |
| Clinical central DBP (mmHg) | 76±1.1 | 70.8±2.5 | 0.06 |
| 24-hour peripheral SBP (mmHg) | 119.8±1.9 | 109.2±4 | 0.02b |
| 24-hour peripheral DBP (mmHg) | 70±1.2 | 65.7±2.5 | 0.13 |
| 24-hour central SBP (mmHg) | 116.4±1.4 | 108.9±3 | 0.02b |
| 24-hour central DBP (mmHg) | 76±0.90 | 73±1.9 | 0.18 |
| AIx (%) | 30.4±1.1 | 25.7±2.4 | 0.07b |
| AIx @ 75bpm (%) | 28.1±0.90 | 26.03±2 | 0.36 |
| 24-hour AIx @ 75bpm (%) | 29±0.75 | 26.6±1.6 | 0.19 |
| 24-hour PWV (m/second) | 9.01±0.09 | 9.04±0.20 | 0.91 |
Notes: All group means, except for age, are age-adjusted.
a
Means are adjusted for MTX dose and duration.
b
P-value≤0.05.
c
P-value≤0.01. Data presented as mean ± standard deviation unless otherwise indicated.
Abbreviations: RBCs, red blood cells; BMI, body mass index; MTX, Methotrexate; MTXPGs, MTX polyglutamates; SBP, systolic blood pressure; DBP, diastolic blood pressure; AIx, Augmentation index; PWV, pulse wave velocity; CRP, C-reactive protein.